C

Carmell Corp
NASDAQ:CTCX

Watchlist Manager
Carmell Corp
NASDAQ:CTCX
Watchlist
Price: 0.153 USD -1.29% Market Closed
Market Cap: 4.6m USD

Relative Value

The Relative Value of one CTCX stock under the Base Case scenario is 0.005 USD. Compared to the current market price of 0.153 USD, Carmell Corp is Overvalued by 97%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTCX Relative Value
Base Case
0.005 USD
Overvaluation 97%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
11
Median 3Y
5.1
Median 5Y
0
Industry
7.1
vs History
vs Industry
8
Median 3Y
-0.6
Median 5Y
-2.5
Industry
22.9
vs History
vs Industry
Median 3Y
-13.8
Median 5Y
-224.7
Industry
19.4
vs History
vs Industry
Median 3Y
-11.5
Median 5Y
-224.7
Industry
22.6
vs History
vs Industry
68
Median 3Y
2
Median 5Y
2
Industry
2.7
vs History
14
vs Industry
11
Median 3Y
4.5
Median 5Y
0
Industry
7.4
vs History
14
vs Industry
7
Median 3Y
0
Median 5Y
0
Industry
9.2
vs History
vs Industry
Median 3Y
-18.9
Median 5Y
-39.2
Industry
4.5
vs History
vs Industry
Median 3Y
-18.6
Median 5Y
-39.2
Industry
4.5
vs History
vs Industry
Median 3Y
-13.4
Median 5Y
-224.7
Industry
5
vs History
vs Industry
Median 3Y
-13.4
Median 5Y
-224.7
Industry
3.7
vs History
vs Industry
69
Median 3Y
1.9
Median 5Y
1.9
Industry
4.9

Multiples Across Competitors

CTCX Competitors Multiples
Carmell Corp Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Carmell Corp
NASDAQ:CTCX
4.6m USD 140.5 -0.2 -0.4 -0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 615 484 -159 769.4 -194 011 -191 797.1
US
Abbvie Inc
NYSE:ABBV
336.9B USD 5.9 81.1 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.6B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
138.8B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.4B USD 10.6 -118.8 25.2 26.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.7 -534.8 -582.3 -566.8
AU
CSL Ltd
ASX:CSL
116.9B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.3B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.9 -66.7 -60.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43B USD 18.3 -159.3 -715.5 -358.5
P/S Multiple
Revenue Growth P/S to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average P/S: 3 056 163.1
140.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 615 484
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 095.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.3
29%
0.6
P/E Multiple
Earnings Growth PEG
US
C
Carmell Corp
NASDAQ:CTCX
Average P/E: 34.5
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 769.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -118.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.8 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average EV/EBITDA: 15.7
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 011 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -715.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average EV/EBIT: 20.3
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 797.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -358.5 N/A N/A